m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00072)
| Target Name | hsa_circ_0092493 (circ_ARL3) | ||||
|---|---|---|---|---|---|
| Gene Name | Circ_ARL3 | ||||
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
Circ_ARL3
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | hsa_circ_0092493 (circ_ARL3) is a critical regulator in HBV-related HCC, targeting the axis of circ-ARL3/miR-1305 can be a promising treatment for HBV+ HCC patients. HBx protein upregulated N6 -methyladenosine (m6A) methyltransferases METTL3 expression, increasing the m6A modification of circ-ARL3; then, m6A reader YTHDC1 bound to m6 A-modified of circ-ARL3 and favored its reverse splicing and biogenesis. Furthermore, circ-ARL3 was able to sponge miR-1305, antagonizing the inhibitory effects of miR-1305 on a cohort of target oncogenes, thereby promoting HBV+ HCC progression. | |||
| Target Regulation | Up regulation | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
| Cell Process | Reverse splicing and biogenesis | |||
| In-vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 |
| In-vivo Model | Mice were randomly divided into three groups, and subcutaneously injected with control, circ-ARL3-silenced and circ-ARL3&miR-1305-silenced HepG2.2.15 cells. | |||
YTH domain-containing protein 1 (YTHDC1) [READER]
| In total 1 item(s) under this regulator | ||||
| Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
| Response Summary | hsa_circ_0092493 (circ_ARL3) is a critical regulator in HBV-related HCC, targeting the axis of circ-ARL3/miR-1305 can be a promising treatment for HBV+ HCC patients. HBx protein upregulated N6 -methyladenosine (m6A) methyltransferases METTL3 expression, increasing the m6A modification of circ-ARL3; then, m6A reader YTHDC1 bound to m6A-modified of circ-ARL3 and favored its reverse splicing and biogenesis. Furthermore, circ-ARL3 was able to sponge miR-1305, antagonizing the inhibitory effects of miR-1305 on a cohort of target oncogenes, thereby promoting HBV+ HCC progression. | |||
| Target Regulation | Up regulation | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12.02 | ||
| Cell Process | Reverse splicing and biogenesis | |||
| In-vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 |
| In-vivo Model | Mice were randomly divided into three groups, and subcutaneously injected with control, circ-ARL3-silenced and circ-ARL3&miR-1305-silenced HepG2.2.15 cells. | |||
Liver cancer [ICD-11: 2C12]
| In total 2 item(s) under this disease | ||||
| Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | hsa_circ_0092493 (circ_ARL3) is a critical regulator in HBV-related HCC, targeting the axis of circ-ARL3/miR-1305 can be a promising treatment for HBV+ HCC patients. HBx protein upregulated N6 -methyladenosine (m6A) methyltransferases METTL3 expression, increasing the m6A modification of circ-ARL3; then, m6A reader YTHDC1 bound to m6 A-modified of circ-ARL3 and favored its reverse splicing and biogenesis. Furthermore, circ-ARL3 was able to sponge miR-1305, antagonizing the inhibitory effects of miR-1305 on a cohort of target oncogenes, thereby promoting HBV+ HCC progression. | |||
| Responsed Disease | Hepatocellular carcinoma [ICD-11: 2C12.02] | |||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Cell Process | Reverse splicing and biogenesis | |||
| In-vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 |
| In-vivo Model | Mice were randomly divided into three groups, and subcutaneously injected with control, circ-ARL3-silenced and circ-ARL3&miR-1305-silenced HepG2.2.15 cells. | |||
| Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
| Response Summary | hsa_circ_0092493 (circ_ARL3) is a critical regulator in HBV-related HCC, targeting the axis of circ-ARL3/miR-1305 can be a promising treatment for HBV+ HCC patients. HBx protein upregulated N6 -methyladenosine (m6A) methyltransferases METTL3 expression, increasing the m6A modification of circ-ARL3; then, m6A reader YTHDC1 bound to m6A-modified of circ-ARL3 and favored its reverse splicing and biogenesis. Furthermore, circ-ARL3 was able to sponge miR-1305, antagonizing the inhibitory effects of miR-1305 on a cohort of target oncogenes, thereby promoting HBV+ HCC progression. | |||
| Responsed Disease | Hepatocellular carcinoma [ICD-11: 2C12.02] | |||
| Target Regulator | YTH domain-containing protein 1 (YTHDC1) | READER | ||
| Target Regulation | Up regulation | |||
| Cell Process | Reverse splicing and biogenesis | |||
| In-vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens | CVCL_0027 |
| In-vivo Model | Mice were randomly divided into three groups, and subcutaneously injected with control, circ-ARL3-silenced and circ-ARL3&miR-1305-silenced HepG2.2.15 cells. | |||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Regulator
Histone modification
m6A Regulator: YTH domain-containing protein 1 (YTHDC1)
| In total 1 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT03482 | ||
| Epigenetic Regulator | Histone acetyltransferase p300 (P300) | |
| Regulated Target | Histone H3 lysine 18 lactylation (H3K18la) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Liver cancer | |
Non-coding RNA
m6A Regulator: YTH domain-containing protein 1 (YTHDC1)
| In total 1 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT05462 | ||
| Epigenetic Regulator | hsa_circ_0092493 (Circ_ARL3) | |
| Regulated Target | microRNA 1305 (MIR1305) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Liver cancer | |
m6A Regulator: Methyltransferase-like 3 (METTL3)
| In total 1 item(s) under this m6A regulator | ||
| Crosstalk ID: M6ACROT05463 | ||
| Epigenetic Regulator | hsa_circ_0092493 (Circ_ARL3) | |
| Regulated Target | microRNA 1305 (MIR1305) | |
| Crosstalk relationship | m6A → ncRNA | |
| Disease | Liver cancer | |